Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207,440,936
-
Total 13F shares
-
74,286,796
-
Share change
-
-6,443,290
-
Total reported value
-
$103,280,863
-
Put/Call ratio
-
28%
-
Price per share
-
$1.39
-
Number of holders
-
121
-
Value change
-
-$10,454,820
-
Number of buys
-
50
-
Number of sells
-
97
Institutional Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q2 2023
As of 30 Jun 2023,
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) was held by
121 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
74,286,796 shares.
The largest 10 holders included
WASATCH ADVISORS LP, ARMISTICE CAPITAL, LLC, Point72 Asset Management, L.P., Meditor Group Ltd, VANGUARD GROUP INC, Bellevue Group AG, PLATINUM INVESTMENT MANAGEMENT LTD, MILLENNIUM MANAGEMENT LLC, Two Seas Capital LP, and Parkman Healthcare Partners LLC.
This page lists
121
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.